The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 3 trial of IMC-F106C (PRAME x CD3) plus nivolumab versus standard nivolumab regimens in HLA-A*02:01+ patients with previously untreated advanced melanoma (PRISM-MEL-301).
 
Georgina V. Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Immunocore Ireland Limited; Innovent Biologics; IO Biotech; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Regeneron
 
Victoria Atkinson
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Nektar; Novartis; Pierre Fabre; Provectus Biopharmaceuticals; QBiotics
Consulting or Advisory Role - Bristol-Myers Squibb; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; QBiotics
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche/Genentech
Expert Testimony - Bristol-Myers Squibb/Celgene
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; OncoSec; Pierre Fabre
 
Paolo Antonio Ascierto
Consulting or Advisory Role - 4SC; Anaveon; AstraZeneca; Bayer; Bio-AI Health; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Erasca, Inc; Idera; Immunocore; Italfarmaco; ITeos Therapeutics; Lunaphore Technologies; Medicenna; Merck Serono; Merck Sharp & Dohme; Nektar; Nouscom; Novartis; OncoSec; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sandoz; Sanofi; Seagen; Sun Pharma; Ultimovacs; ValoTx
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bio-AI Health; MSD Oncology; Pfizer; Pierre Fabre; Replimune
 
Diwakar Davar
Honoraria - ACM Biolabs; Clinical Care Options (CCO); Gerson Lehrman Group; Medical Learning Group; Merck; Xilio Therapeutics
Consulting or Advisory Role - ACM Bio; Ascendis Pharma; Clinical Care Options; Gerson Lehrman Group; Replimune; TriSalus Life Sciences; Xilio Therapeutics
Speakers' Bureau - Castle Biosciences
Research Funding - Arcus Biosciences; CellSight Technologies; Checkmate Pharmaceuticals; GlaxoSmithKline; Merck; Merck; Zucero Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Application No.: 63/124,231; Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy
 
Omid Hamid
Stock and Other Ownership Interests - Bactonix
Honoraria - Bristol-Myers Squibb; Immunocore; Novartis; Pfizer; Regeneron
Consulting or Advisory Role - Alkermes; Amgen; Bactonix; BeiGene; BioAtla; Bristol-Myers Squibb; Eisai; Genentech; Georgiamune; GigaGen; GlaxoSmithKline; Grit Biotechnology; Idera; Immunocore; Incyte; Instil Bio; IO Biotech; Iovance Biotherapeutics; Janssen; KSQ Therapeutics; Merck; Moderna Therapeutics; NGM Biopharmaceuticals; Novartis; Obsidian Therapeutics; Pfizer; Regeneron; Roche; Sanofi; Seagen; Tempus; Vial; Zelluna
Speakers' Bureau - Bristol-Myers Squibb; Immunocore; Novartis; Pfizer; Regeneron
Research Funding - Aduro Biotech (Inst); Akeso Biopharma (Inst); Amgen (Inst); Arcus Biosciences (Inst); Bioatla (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Merck Serono (Inst); Moderna Therapeutics (Inst); NextCure (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Torque (Inst); Zelluna (Inst)
 
Caroline Robert
Stock and Other Ownership Interests - RiboNexus
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Sun Pharma
Research Funding - Novartis (Inst); Phio Pharmaceuticals (Inst)
 
Marcus O. Butler
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Roche; Sanofi
Consulting or Advisory Role - Adaptimmune; Adaptimmune; Bristol-Myers Squibb; EMD Serono; Genzyme; GlaxoSmithKline; GlaxoSmithKline; IDEAYA Biosciences; Immunocore; Immunovaccine; Instil Bio; Iovance Biotherapeutics; LaRoche Posay; Medison; Merck; Novartis; Pfizer; Regeneron; Sanofi; Sun Pharma
Research Funding - Merck (Inst); Novartis Canada Pharmaceuticals Inc (Inst); Takara Bio (Inst)
Expert Testimony - Merck
 
Reinhard Dummer
Honoraria - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; T3 Pharmaceuticals; Takeda; touchIME
Consulting or Advisory Role - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Sun Pharma; T3 Pharmaceuticals; Takeda; touchIME
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Christine Hafner
No Relationships to Disclose
 
Muhammad Adnan Khattak
Honoraria - Evaxion Biotech
Consulting or Advisory Role - Moderna Therapeutics
Travel, Accommodations, Expenses - Evaxion Biotech; Moderna Therapeutics; Pierre Fabre
 
James Larkin
Honoraria - Agence Unik; Bristol-Myers Squibb; Cambridge Healthcare research; Eisai; Incyte; Merck Serono; Novartis; Pfizer; RCGP; Royal College of Physicians; touchEXPERTS; touchIME; VJOncology
Consulting or Advisory Role - Agence Unik; Apple Tree Partners; Aptitude Health; AstraZeneca; Bristol-Myers Squibb; Calithera Biosciences; Debiopharm Group; eCancer; Eisai; EUSA Pharma; GlaxoSmithKline; Goldman Sachs; Incyte; Insel Gruppe; iOnctura; Ipsen; Merck Serono; MSD Oncology; Novartis; Pfizer; Philogen; Pierre Fabre; Roche; Syncona; Telix Pharmaceuticals; Ultimovacs
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Roche; ESMO; GlaxoSmithKline; immatics; Pierre Fabre; Roche/Genentech
 
Paul Lorigan
Stock and Other Ownership Interests - Supportive Care; The Christie Private Care
Honoraria - BMS; Merck; MLA Dx; MSD; NeraCare GmbH; Ultimovacs
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; NeraCare GmbH
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme
Research Funding - BMS (Inst); Pierre Fabre (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Meredith McKean
Consulting or Advisory Role - Castle Biosciences (Inst); IQVIA (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
Research Funding - AADi (Inst); Alpine Immune Sciences (Inst); Arcus Biosciences (Inst); Arvinas (Inst); Ascentage Pharma Group (Inst); ASCO (Inst); Astellas Pharma (Inst); Aulos Bioscience (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioMed Valley Discoveries (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Foghorn Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Immvira (Inst); Infinity Pharmaceuticals (Inst); Jacobio (Inst); Kechow Pharma (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Mereo BioPharma (Inst); Metabomed (Inst); Moderna Therapeutics (Inst); NBE Therapeutics (Inst); Nektar (Inst); Novartis (Inst); NucMito Pharmaceuticals (Inst); OncoC4 (Inst); Oncorus (Inst); OnKure (Inst); PACT Pharma (Inst); Pfizer (Inst); Plexxikon (Inst); Poseida (Inst); Prelude Therapeutics (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Scholar Rock (Inst); Seagen (Inst); Synthorx (Inst); Tempest Therapeutics (Inst); TeneoBio (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Top Alliance BioScience (Inst); Xilio Therapeutics (Inst)
 
Rino S. Seedor
Research Funding - Bristol-Myers Squibb (Inst); HUYA Bioscience International (Inst); Immunocore (Inst); Regeneron (Inst)
 
Heather May Shaw
Consulting or Advisory Role - Bristol-Myers Squibb; CDR-Life; Genzyme; Mallinckrodt/Therakos; MSD Oncology; Novartis; Regeneron; Scancell Ltd.
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Novartis; Sanofi
Research Funding - Agenus (Inst); AstraZeneca/MedImmune (Inst); Genmab (Inst); IDEAYA Biosciences (Inst); Idera (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Roche (Inst); Scancell Ltd. (Inst)
Expert Testimony - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Agenus; Bristol-Myers Squibb; Merck Sharp & Dohme; Regeneron
(OPTIONAL) Uncompensated Relationships - iOnctura
 
Joe Stephenson
No Relationships to Disclose
 
Yuan Yuan
Employment - Immunocore
Stock and Other Ownership Interests - Immunocore
Consulting or Advisory Role - G1 Therapeutics (I); Precision Scientific (I)
 
Roma Patel
Employment - GlaxoSmithKline; Immunocore
Stock and Other Ownership Interests - GlaxoSmithKline; Immunocore; Novartis
 
Piruntha Thiyagarajah
Employment - Immunocore; Reckitt Benckiser (I)
Stock and Other Ownership Interests - AstraZeneca/MedImmune
 
Dirk Schadendorf
Honoraria - 4SC; Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Japan; Erasca, Inc; immatics; Immunocore; InflarxGmbH; LabCorp; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Novigenix; Pamgene; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sanofi/Regeneron; Seagen; Sun Pharma; Ultimovacs
Consulting or Advisory Role - Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Erasca, Inc; immatics; Immunocore; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Pierre Fabre; Replimune; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron